Updated: Alnylam’s new Phase 3 ATTR data bring uncertainty to standard of care ambitions

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

FDA will not meet ahead of bluebird bio’s sickle cell disease gene therapy PDUFA date – Pharmaceutical Technology

bluebird bio’s therapy aims to treat the underlying genetic cause of sickle cell disease – a group of conditions that approximately 100,000 Americans currently live

August 16, 2023

Google Searches for “AI in Healthcare” Up by 300% in 3 Years

What You Should Know: – An analysis of “AI in Healthcare” related Google search data from 2020 to 2023 increased by over 300%, according to

September 19, 2023

Marc Tessier-Lavigne steps down from Regeneron board

Marc Tessier-Lavigne stepped down from Regeneron’s board of directors. The move comes after he resigned as Stanford University’s president following a scientific misconduct investigation. Regeneron

September 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.